Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
C Rolfo, E Giovannetti, DS Hong, T Bivona… - Cancer treatment …, 2014 - Elsevier
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
Current strategies for treating NSCLC: from biological mechanisms to clinical treatment
J Li, HF Kwok - Cancers, 2020 - mdpi.com
The identification of specific epidermal growth factor receptor (EGFR)-activating mutations
heralded a breakthrough in non-small-cell lung cancer (NSCLC) treatments, with the …
heralded a breakthrough in non-small-cell lung cancer (NSCLC) treatments, with the …
[HTML][HTML] Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel …
M Johnson, MC Garassino, T Mok, T Mitsudomi - Lung Cancer, 2022 - Elsevier
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients
L Lin, TG Bivona - Chemotherapy research and practice, 2012 - Wiley Online Library
The epidermal growth factor receptor (EGFR) is a well‐characterized oncogene that is
frequently activated by somatic kinase domain mutations in non‐small cell lung cancer …
frequently activated by somatic kinase domain mutations in non‐small cell lung cancer …
EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now?
YL Wu - Trends in Pharmacological Sciences, 2016 - cell.com
Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …
[HTML][HTML] Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
L Dong, D Lei, H Zhang - Oncotarget, 2017 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) mutations (EGFRm+) occur in 10–35% of non-
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …
Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer
A Nakata, N Gotoh - Expert opinion on therapeutic targets, 2012 - Taylor & Francis
Introduction: The epidermal growth factor receptor (EGFR) and its family members are
involved in many aspects of tumor biological processes. Aberrant activation of the EGFR …
involved in many aspects of tumor biological processes. Aberrant activation of the EGFR …
[HTML][HTML] The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
KR Jakobsen, C Demuth, BS Sorensen… - … lung cancer research, 2016 - ncbi.nlm.nih.gov
Inhibition of the epidermal growth factor receptor (EGFR) is an important strategy when
treating non-small cell lung cancer (NSCLC) patients. However, intrinsic resistance or …
treating non-small cell lung cancer (NSCLC) patients. However, intrinsic resistance or …
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor …
KSH Nguyen, S Kobayashi, DB Costa - Clinical lung cancer, 2009 - Elsevier
Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
[HTML][HTML] Strategies to improve outcomes of patients with EGFR-mutant non–small cell lung cancer: review of the literature
C Zhou, L Di Yao - Journal of Thoracic Oncology, 2016 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …